TNF and early-onset autosomal dominant Alzheimer disease: An intriguing candidate for specifically inhibiting soluble TNFα without impairing protective juxtacrine TNFα signaling is the brain-permeant biologic XPro1595 [68], currently in phase 1b testing in patients with Alzheimer’s disease (NCT03943264).